Has Alok Maheshwari, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,761 in general payments to Alok Maheshwari, MD across 176 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alok Maheshwari, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alok Maheshwari, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alok Maheshwari, MD

Interventional Cardiology · Robbinsdale, MNNPI 1003896150

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.5%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Medtronic at 38.1% of the total.

$10,761in general payments, 2019–2025

Across 176 payments — averaging $61.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$4K
Abbott$4K
Edwards Lifesciences$1K
Boston Scientific$804
Inari Medical, Inc.$390
W. L. Gore & Associates, Inc.$207
plus $218 from 4 others

$250,883in research payments, 2019–2025

Across 12 payments — averaging $20,907 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$251K

What the payments were for

Grants$2252%
Travel & lodging$4,56142%
Food & beverage$5,97556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	100	$4,101
Abbott	33	$4,026
Edwards Lifesciences	15	$1,015
Boston Scientific	18	$804
Inari Medical, Inc.	2	$390
W. L. Gore & Associates, Inc.	3	$207
Shockwave Medical, Inc	2	$164
Philips North America LLC	1	$22
Cardiva Medical, Inc.	1	$19
Terumo Medical Corporation	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TRICLIP$2,027
CoreValve Evolut$1,318
MitraClip$945
Edwards SAPIEN 3 Transcatheter Heart Valve$615
COREVALVE EVOLUT R$468
FLOWTRIEVER CATHETER, S$390
CT THROMBECTOMY SYSTEM KIT$390
WATCHMAN Access System$236
NAVITOR$201
Telescope$158
GORE CARDIOFORM Septal Occluder$128
GENERAL - STRUCTURAL HEART$125
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
Watchman$109
XIENCE SIERRA$102

How this compares

$10,761 in reported general payments places this provider in the 65th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$70,448

Medicare patients

450

Services billed

934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	150	$184,875
XareltoRivaroxaban	35	$53,227
Repatha SureclickEvolocumab	23	$34,988
Metoprolol Succinate	376	$8,127
Atorvastatin Calcium	267	$3,894
Digoxin	13	$3,064
Lisinopril	120	$1,407
ClopidogrelClopidogrel Bisulfate	98	$1,363
Ezetimibe	44	$1,334
Isosorbide Mononitrate ErIsosorbide Mononitrate	44	$1,234
Losartan Potassium	82	$1,200
Furosemide	91	$680
Rosuvastatin Calcium	53	$665
Metoprolol Tartrate	49	$660
Amlodipine Besylate	70	$593

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Robbinsdale

Sumit PatelRobbinsdale$42K
Sara MurrayRobbinsdale$8K
Abdisamad IbrahimRobbinsdale$5K
Thom DahleSaint Cloud$1.1M
Stephen KiddSaint Cloud$607K
Brian StegmanSt Cloud$587K
Emmanouil BrilakisMinneapolis$548K
Wesley PedersenMinneapolis$493K
Michael ManolesMinneapolis$201K
Jay TraverseMinneapolis$198K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →